Title Association between C-reactive protein levels in the first 1-3 days post-transplant and allogeneic immune reactions
Authors Chen, Yao
Huang, Xiao-Jun
Liu, Kai-Yan
Chen, Huan
Chen, Yu-Hong
Zhang, Xiao-Hui
Wang, Yu
Wang, Feng-Rong
Han, Wei
Wang, Jing-Zhi
Yan, Chen-Hua
Xu, Lan-Ping
Affiliation Peking Univ, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China.
Keywords C-reactive protein
engraftment syndrome
graft-versus-host disease
aploidentical
stem cell transplantation
STEM-CELL TRANSPLANTATION
VERSUS-HOST-DISEASE
CORD-BLOOD TRANSPLANTATION
BONE-MARROW-TRANSPLANTATION
ENGRAFTMENT SYNDROME
HEMATOLOGICAL MALIGNANCIES
NONRELAPSE MORTALITY
MAJOR COMPLICATIONS
HEMATOPOIETIC SCT
SERUM-LEVELS
Issue Date 2017
Publisher BIOMARKERS IN MEDICINE
Citation BIOMARKERS IN MEDICINE.2017,11(2),117-124.
Abstract Aim: The purpose of this study was to determine whether C-reactive protein (CRP) in the first 1-3 days post-transplant could predict allogeneic immune reactions, including engraftment syndrome or acute graft-versus-host disease (GVHD), in pediatric haploidentical stem cell transplantation. Patients & methods: The study population comprised 175 consecutive pediatric patients. Receiver operating characteristic analysis was performed to identify the cut-off CRP value. Results: The high-CRP group (>= 20.1 mg/ l) was associated with an increased occurrence of engraftment syndrome (hazard ratio [HR] = 2.046; p = 0.008), II-IV acute GVHD (HR = 2.203; p = 0.001) and severe GVHD (HR = 6.371; p = 0.004). Conclusion: Our data suggest that higher CRP during the first 1-3 days post-transplant could be a predictor of allogeneic immune reactions.
URI http://hdl.handle.net/20.500.11897/475465
ISSN 1752-0363
DOI 10.2217/bmm-2016-0244
Indexed SCI(E)
Appears in Collections: 医学部待认领

Files in This Work
There are no files associated with this item.

Web of Science®


0

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.